MGX (Metagenomi Therapeutics) Net Margin %: -1,847.68% (As of Mar. 2026)


MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.19
! 4 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics Net Margin %?

Metagenomi Therapeutics MGX -1.08% 10 Net Margin % is -1,847.68% as of Mar. 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 947 Biotechnology companies, Metagenomi Therapeutics ranks worse than 68.22% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Metagenomi Therapeutics's Net Income for the three months ended in Mar. 2026 was $-23.06 Mil. Metagenomi Therapeutics's Revenue for the three months ended in Mar. 2026 was $1.25 Mil. Therefore, Metagenomi Therapeutics's net margin for the quarter that ended in Mar. 2026 was -1,847.68%.

The historical rank and industry rank for Metagenomi Therapeutics's Net Margin % or its related term are showing as below:

MGX' s Net Margin % Range Over the Past 10 Years
Min: -8823.87   Med: -253.45   Max: -149.26
Current: -384.61

MGX's Net Margin % is ranked worse than
68.22% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs MGX: -384.61

Metagenomi Therapeutics  (NAS:MGX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Metagenomi Therapeutics Net Margin % Related Terms

Metagenomi Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Metagenomi Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Therapeutics Net Margin % Chart

Metagenomi Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
-8,823.87 -253.45 -152.50 -149.26 -348.54

Metagenomi Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -606.71 -233.85 -235.51 -576.02 -1,847.68

MGX vs HYPD, ATYR, ACTU: Net Margin % Comparison

For the Biotechnology subindustry, Metagenomi Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Metagenomi Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Metagenomi Therapeutics's Net Margin % falls into.


MGX
10GF Score
Metagenomi Therapeutics Inc MGX
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metagenomi Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Metagenomi Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-87.868/25.21
=-348.54 %

Metagenomi Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-23.059/1.248
=-1,847.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -1,847.68% mean?
Metagenomi Therapeutics (MGX) has a Net Margin % of -1,847.68% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Metagenomi Therapeutics and its competitors. According to the industry distribution chart, Metagenomi Therapeutics ranks #646 out of 947 companies in the Biotechnology industry, placing it in the top 68.2%.
Is Metagenomi Therapeutics' Net Margin % too high?
Metagenomi Therapeutics' current Net Margin % is -1,847.68%. Based on the distribution chart, Metagenomi Therapeutics ranks #646 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' Net Margin % compare to HYPD and ATYR?
According to the Biotechnology industry distribution chart, Metagenomi Therapeutics ranks #646 out of 947 companies for Net Margin %. This places Metagenomi Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current Net Margin % is -1,847.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current Net Margin % of -1,847.68%. The current Net Margin % is -1,847.68%. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current Net Margin % is -1,847.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.19
Price